Nektar Therapeutics (NKTR) Share buybacks
- Total buybacks · last 12 months (USD): Value $0.00; Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2025-12-31..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2025-12-31..
Share buybacks
Overview →Financial period ending 2025-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | $0.00 | Trailing-year cash paid for share repurchases. Period ending 2025-12-31. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2025-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | 0.00 USD | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2025-12-31 | $0.00 | (m) | (m) |
| 2025-09-30 | $0.00 | (m) | (m) |
| 2025-06-30 | $0.00 | (m) | (m) |
| 2025-03-31 | $0.00 | (m) | (m) |
| 2024-12-31 | $3.00M | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |